Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OPtimizing REperfusion by Primary Intra-Arterial ThRomboLysis for Medium Vessel Occlusion (PEARL-MeVO): A Multicenter, Prospective, Randomized Controlled, Open-label, Blinded-Endpoint Clinical Trial

NCT07137832 is registered in ClinicalTrials.gov with Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University as lead sponsor.

NCT NCT07137832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07137832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OPtimizing REperfusion by Primary Intra-Arterial ThRomboLysis for Medium Vessel Occlusion (PEARL-MeVO): A Multicenter, Prospective, Randomized Controlled, Open-label, Blinded-Endpoint Clinical Trial
Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase
Phase 3
Overall status
Recruiting
Start date
October 9, 2025
Completion date
December 31, 2028
Enrollment
530 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke